Articles by Marc Hurlbert, Ph.D., MRA Chief Science Officer
Overcoming Targeted Therapy Resistance
Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.
Melanoma Treatment Advances – 2018 in Review
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
Melanoma Mortality Rates Decreasing Despite Ongoing Increase in Incidence Rates
The American Cancer Society released updated estimates for the incidence, prevalence, and survival statistics for cancer in the United States. For 2019, ACS estimates that 96,480 people will be diagnosed with melanoma and that 7,230 Americans will die due to the disease. This is an increase of 5.6% and a decrease of 19% from last year respectively.
About the Author
Marc Hurlbert, Ph.D., MRA Chief Science Officer
Dr. Marc Hurlbert, a pharmacologist by training, serves as Chief Science Officer for the Melanoma Research Alliance. In this role, he is responsible for guiding MRA’s scientific strategy, overseeing the peer-reviewed grant-making program, and forging scientific collaborations. He has more than 18 years of nonprofit and grant-making experience focused on advancing medical research. Past work has included treatment and prevention strategies for breast cancer, lymphoma and multiple myeloma, as well as juvenile diabetes. In addition, Marc led the expansion of public health programs to enable low-income, uninsured and minority patient populations diagnosed with cancer to access treatments and care across the US, and in developing countries around the world.
Dr. Hurlbert comes to MRA after serving for three years as the Chief Mission Officer at the Breast Cancer Research Foundation (BCRF). At BCRF Marc oversaw a $60-million annual research program supporting 300 scientists in 15 countries, spanning all aspects of cancer from basic biology and prevention, to developing new treatments and to quality of life research. Prior to BCRF, Marc served as a scientific director at the Avon Foundation Breast Cancer Crusade, as a scientific consultant and on the staff of the Juvenile Diabetes Research Foundation (JDRF).
In 2013, Dr. Hurlbert co-founded and served as Chair for the Metastatic Breast Cancer Alliance, a leading coalition of 30 nonprofits, 11 pharmaceutical companies, and dozens of patients that works together to advance research and improve the quality of life for patients with metastatic disease. During his five years as Chair, the Alliance conducted and published a comprehensive research landscape analysis, conducted two national awareness campaigns reaching millions of people, developed two new tools for patients to find clinical trials, forged partnerships with NCI and the FDA, and conducted 4 epidemiology research studies.
He earned a Ph.D. in Pharmacology from the University of Colorado, and completed a fellowship at the New York University Medical Center. He has a Bachelor of Science degree in Biochemistry from the University of Kansas.